PT  - JOURNAL ARTICLE
AU  - Andrea T. Hooper
AU  - Selin Somersan-Karakaya
AU  - Shane E. McCarthy
AU  - Eleftherios Mylonakis
AU  - Shazia Ali
AU  - Jingning Mei
AU  - Rafia Bhore
AU  - Adnan Mahmood
AU  - Gregory P. Geba
AU  - Paula Dakin
AU  - David M. Weinreich
AU  - George D. Yancopoulos
AU  - Gary A. Herman
AU  - Jennifer D. Hamilton
AU  - the COVID-19 Phase 2/3 Hospitalized Trial Team
TI  - Casirivimab and Imdevimab Treatment in Seropositive, Hospitalized COVID-19 Patients With Non-neutralizing or Borderline Neutralizing Antibodies
AID  - 10.1101/2022.06.14.22276389
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.06.14.22276389
4099  - http://medrxiv.org/content/early/2022/06/14/2022.06.14.22276389.short
4100  - http://medrxiv.org/content/early/2022/06/14/2022.06.14.22276389.full
AB  - We conducted a post-hoc analysis in seropositive patients who were negative or borderline for functional neutralizing antibodies (nAbs) against SARS-CoV-2 at baseline from a phase 1/2/3 trial of casirivimab and imdevimab (CAS+IMD) treatment in hospitalized COVID-19 patients on low-flow or no supplemental oxygen prior to the emergence of Omicron-lineage variants. Patients were randomized to a single dose of 2.4 g CAS+IMD, 8.0 g CAS+IMD, or placebo. Patients seropositive for anti-SARS-CoV-2 antibodies at baseline were analyzed by their baseline nAb status. At baseline, 20.6% (178/864) of seropositive patients were negative/borderline for nAbs. CAS+IMD reduced viral load in patients who were negative/borderline for nAbs versus placebo, but not in patients who were positive for nAbs. We observed a trend in reduction of the proportion of patients who died or required mechanical ventilation (MV), as well as in all-cause mortality, by day 29 with CAS+IMD versus placebo in patients who were negative/borderline for nAbs. In those who were negative/borderline for nAbs, the proportions who died/needed MV from days 1–29 were 19.1% and 10.9%, and the proportions of patients who died from days 1–29 were 16.2% and 9.1%, in the placebo and CAS+IMD combined dose groups, respectively. No measurable harm or benefit in death/MV or all-cause mortality was observed in patients who were positive for nAbs. In hospitalized COVID-19 patients on low-flow or no supplemental oxygen, CAS+IMD reduced viral load, the risk of death or MV, and all-cause mortality in seropositive patients who were negative/borderline for nAbs.Importance The clinical benefit of CAS+IMD in hospitalized seronegative patients with COVID-19 has previously been demonstrated, although these studies observed no clinical benefit in seropositive patients. As the prevalence of SARS-CoV-2 seropositive individuals rises due to both vaccination and previous infection, it is important to understand whether there is a subset of hospitalized patients with COVID-19, who have antibodies against SARS-CoV-2, who could benefit from anti-SARS-CoV-2 monoclonal antibody treatment. This post-hoc analysis demonstrates that there is a subset of hospitalized, seropositive patients with inadequate SARS-CoV-2 nAbs (ie, those who were negative or borderline for nAbs) who may still benefit from CAS+IMD treatment if infected with a susceptible variant. Therefore, utilizing seronegativity status alone to guide treatment decisions for patients with COVID-19 may fail to identify seropositive patients who could benefit from anti-SARS-CoV-2 monoclonal antibody therapies which retain activity against circulating strains, depending on how effectively their endogenous antibodies neutralize SARS-CoV-2.Competing Interest StatementATH is a Regeneron Pharmaceuticals, Inc. employee/stockholder; a former Pfizer employee and current stockholder; has a patent pending with Regeneron Pharmaceuticals, Inc.; and reports grants from BARDA. SS-K, SEM, JM, RB, AM, PD, and DMW are Regeneron Pharmaceuticals, Inc. employees/stockholders; and report grants from BARDA. EM reports payments to his institution received from NIH/NIAID, NIH/NIGMS, SciClone Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Pfizer, Chemic Labs/KODA Therapeutics, Cidara, and Leidos Biomedical Research Inc./NCI. SA is a former Regeneron Pharmaceuticals, Inc. employee and current stockholder; and reports grants from BARDA. GDY is a Regeneron Pharmaceuticals, Inc. employee/stockholder; has issued (U.S. Patent Nos. 10,787,501, 10,954,289, and 10,975,139) and pending patents, which have been licensed and receiving royalties, with Regeneron Pharmaceuticals, Inc.; and reports grants from BARDA. GAH and JDH are Regeneron Pharmaceuticals, Inc. employees/stockholders; and have a patent pending, which has been licensed and receiving royalties, with Regeneron Pharmaceuticals, Inc.Clinical TrialNCT04426695Funding StatementThis work was supported by Regeneron Pharmaceuticals, Inc. Certain aspects of this project were supported by federal funds from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, and Biomedical Advanced Research and Development Authority, under OT number HHSO100201700020C.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval for the COVID-19 Phase 2/3 Hospitalized Trial (COV-2066) was obtained from the following ethics review boards: Comissao de Etica para Analise de Projetos de Pesquisa do HCFMUSP, Sao Paulo, Brazil; Comite De Etica Em Pesquisa Prof. Dr. Celso Figueiroa Hospital, Salvador, Bahia, Brazil; Comite de Etica em Pesquisa da Faculdade de Medicina de Botucatu, Sao Paulo, Brazil; Comite de Etica em Pesquisa da Universidade de Passo Fundo, Rio Grande do Sul, Brazil; Comite de Etica em Pesquisa Envolvendo Seres Humanos da Universidade Comunitaria da Servidao Anjo da Guarda, Santa Catarina, Brazil; Comite de Etica em Pesquisa do Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil; Comite de Etica em Pesquisa emSeres Humanos do Hospital das Clinicas da UFPR, Parana, Brazil; Comite de Etica em Pesquisa do Conjunto Hospitalar do Mandaqui, Sao Paulo, Brazil; Comite de etica de la Investigacion de Clinica Las Condes, Santiago, Chile; Comite Etico Cientifico Facultad de Medicina Clinica Alemana Universidad del Desarrollo, Santiago, Chile; Comite de Etica en Investigacion del Nuevo Hospital Civil de Guadalajara "Dr. Juan I Menchaca", Guadalajara, Mexico; Comite de Etica en Investigacion del Centro de Especialidades Medicas del Sureste, Merida, Yucatan, Mexico; Comite de Etica en Investigacion del Hospital General de Culiacan, Culiacan, Mexico; Comite de etica en Investigacion de Medica Sur, S.A.B de C.V., Ciudad de Mexico, Mexico; Comite de Etica en Investigacion del Hospital La Mision, Monterrey, Mexico; Hospital General de Occidente, Zapopan, Mexico; National Centre of Health Management, Chisinau, Republic of Moldova; Comisia Nationala de Bioetica a Medicamentului si Dispozitivelor Medicale, Bucuresti, Romania; Western Institutional Review Board, Puyallup, WA, USA; Providence St. Joseph Institutional Review Board, Renton, WA, USA; Tufts Health Sciences IRB, Boston, MA, USA; Providence Health and Services IRB, Portland, OR, USA; Lifespan IRB, Providence, RI, USA; St. Vincent Hospital and Health Care Center, Inc., Office of Clinical Trials, Indianapolis, IN, USA; BRANY, New Hyde Park, NY, USA; Institutional Review Board, University of Nebraska Medical Center, Omaha, NE, USA; Spectrum Health IRB, Grand Rapids, MI, USA; Research Compliance Office, Stanford University, Palo Alto, CA, USA; and Providence St. Joseph Health (PSJH) Institutional Review Board, Irvine, CA, USA.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesQualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, and statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymized participant data will be considered for sharing once the product and indication has been approved by major health authorities (eg, Food and Drug Administration, European Medicines Agency, Pharmaceuticals and Medical Devices Agency, etc.), if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification. Requests should be submitted to https://vivli.org/. https://vivli.org/